Document:

Exhibit 10.8

 

NANO VIBRONIX, INC.

 

FIRST AMENDMENT TO

SUBSCRIPTION AGREEMENT

SERIES B CONVERTIBLE PREFERRED STOCK

AND WARRANTS

 

FIRST AMENDMENT TO SUBSCRIPTION
AGREEMENT SERIES B CONVERTIBLE PREFERRED STOCK AND WARRANTS (this “Amendment”) dated as of November 14,
2011 between Nano Vibronix, Inc., a Delaware corporation (the “Company”), and the persons who execute this
agreement as investors (collectively, the “Investors”).

 

WITNESSETH:

 

WHEREAS, the
Company entered into a Subscription Agreement Series B Convertible Preferred Stock and Warrants, dated as of March 20, 2009
with the persons who executed such agreement as investors (the “Subscription Agreement”);

 

WHEREAS, pursuant to
Section 5.8 of the Subscription Agreement, any provision of the Subscription Agreement may be amended with the written consent
of the Company and the holders of a majority of the aggregate then-outstanding shares of Series B Convertible Preferred Stock of
the Company;

 

WHEREAS, the Company
and the holders of a majority of the aggregate outstanding shares of Series B Convertible Preferred Stock desire to amend Section
4.2(a) of the Subscription Agreement as set forth below.

 

NOW, THEREFORE, in consideration
of the mutual covenants contained herein, the parties hereto hereby agree as follows:

 

1. Section 4.2(a) of the Subscription Agreement
is hereby deleted and replaced by the following:

 

(a) In the event that an Issuance
Conversion Event shall occur during the Conversion Period, the Securities purchased under this Agreement (including Warrants which
shall have been exercised as of such date and any Underlying Shares purchased pursuant to such Warrants) shall automatically be
cancelled and shall represent solely the right to receive:

 

(i)  such
number of Issuance Conversion Event securities which would have been issued to such Investor pursuant to the terms of such Issuance
in consideration for the sum of: (1) the purchase price paid by the Investor hereunder, (2) any purchase price previously paid
in connection with any prior exercise of the Warrants, plus (3) simple interest at 8% per annum from the date of payment of such
amounts provided that   the purchase price for such Issuance Conversion Event securities shall be deemed reduced by
thirty (30%) percent provided further that   in the case of an Issuance Conversion Event in which notes convertible
into shares in the Company are issued, (A) the conversion price set forth in such notes shall be reduced by thirty (30%) percent,
and (B) the purchase price for such notes shall not be deemed reduced by thirty (30%) percent; and

 

    	 

    	 

    

 

(ii) warrants
in the form attached hereto as Exhibit A, to purchase such number of securities as shall equal thirty (30%) percent of the number
of Issuance Conversion Event securities issued to the Investor pursuant to Section 4.2(a)(i) hereof, at an exercise price equal
to seventy (70%) percent of the purchase price to investors in the Issuance Conversion Event provided that   in the
case of an Issuance Conversion Event in which notes convertible into shares are issued, (A) the warrants shall grant the right
to purchase such number of shares as shall equal thirty (30%) percent of the number of shares issuable upon conversion of the note
issued to the Investor pursuant to Section 4.2(a)(i) hereof and (B) the exercise price under such warrants shall be equal to the
conversion price in the note issued to the Investor pursuant to Section 4.2(a)(i) hereof.

The liquidation preference (if
any) of any preferred shares issued in such Issuance Conversion Event or upon conversion or exercise of such warrants or convertible
notes shall reflect such reduced purchase price.

 

2. The parties acknowledge that the full
execution by the investors listed on the signature page hereof shall constitute the consent of a majority of the aggregate outstanding
shares of Series B Participating Convertible Preferred Stock of the Company.

 

3. The Subscription Agreement otherwise
remains in full force and effect.

 

IN WITNESS WHEREOF, the undersigned have executed this Amendment
as of the 14 day of November, 2011.

 

Nano Vibronix, Inc.

 

	By:	Harold Jacob	 

 

Investors:

	/s/ JB	 
	INTERNATIONAL
    B MANAGEMENT COMPANY LTD.	 
	AMERICAN
    INVESTMENTS LIMITED	 
	(SIGNED
    BY IBMC, DIRECTOR)	 
	/s/
    Joseph Bronner	 
	/s/
    Jonathan Kahan	 
	/s/
    Alexandria Kelly	 
	/s/
    Miriam Winder Kelly	 
	/s/
    Harold Jacob for MIDI	 
	/s/
    Ira Greenstein	 
	/s/
    Stephen Zuller	 
	/s/ Paul Packer

                                                                                Globis Capital Partners
	 
	/s/ Paul Packer	 
	/s/ Paul Packer

                                                                                Globis Overseas Fund
	 
	/s/
    David Kreinberg	 

 

    	 

    	 

    

 

EXHIBIT A

 

	Void after November 15, 2018	Warrant No. ________

 

This Warrant and any shares acquired
upon the exercise of this Warrant have not been registered under the Securities Act of 1933. This Warrant and such shares may not
be sold or transferred in the absence of such registration or an exemption therefrom under said Act. This Warrant and such shares
may not be transferred except upon the conditions specified in this Warrant, and no transfer of this Warrant or such shares shall
be valid or effective unless and until such conditions shall have been complied with.

 

NANO VIBRONIX, INC.

 

FORM OF SERIES B-2 PARTICIPATING CONVERTIBLE
PREFERRED STOCK PURCHASE WARRANT

 

Nano Vibronix, Inc. (the “Company”), having
its principal office at 601 Chestnut Street, Cedarhurst, NY 11516, hereby certifies that, for value received, _____________ (“Investor”),
or assigns, is entitled, subject to the terms set forth below, to purchase from the Company at any time on, or from time to time
after, November___, 2011 and before 5:00 P.M., New York City time, on November 15 , 2018, or as curtailed in accordance with the
terms hereof (the “Expiration Date”), ______________ fully paid and non-assessable shares of Warrant Shares
of the Company, at the Purchase Price per share of $0.199. The number and character of such shares of Warrant Shares and the Purchase
Price per share are subject to adjustment as provided herein.

 

As used herein, the following terms have the following respective
meanings:

 

“Warrant Shares” means the Series B-2 Participating
Convertible Preferred Stock of the Company Stock, par value $0.001 per share, of the Company.

 

“Exchange Act” means the Securities Exchange
Act of 1934 as the same shall be in effect at the time.

 

“Holder” means any record owner of this Warrant.

 

“Per Share Market Value” has the meaning
set forth in Section 2.3.

 

“Original Issue Date” means November ___,
2011.

 

“Other Securities” refers to any stock (other
than Warrant Shares) and other securities of the Company or any other entity which the Holder of this Warrant at any time shall
be entitled to receive, or shall have received, upon the exercise of this Warrant, in lieu of or in addition to Warrant Shares,
or which at any time shall be issuable or shall have been issued in exchange for or in replacement of Warrant Shares or Other Securities
pursuant to Section 5 or otherwise.

 

    	 

    	 

    

 

“Securities Act” means the Securities Act
of 1933 as the same shall be in effect at the time.

 

“Underlying Securities” means any Warrant
Shares or Other Securities issued or issuable upon exercise of this Warrant.

 

“Warrant” means, as applicable, this Warrant
or each right as set forth in this Warrant to purchase one share of Warrant Shares, as adjusted.

 

1.           Sale
or Exercise Without Registration. If, at the time of any exercise, transfer or surrender for exchange of a Warrant or of Underlying
Securities previously issued upon the exercise of Warrants, such Warrant or Underlying Securities shall not be registered under
the Securities Act, the Company may require, as a condition of allowing such exercise, transfer or exchange, that the Holder or
transferee of such Warrant or Underlying Securities, as the case may be, furnish to the Company an opinion of counsel, reasonably
satisfactory to the Company, to the effect that such exercise, transfer or exchange may be made without registration under the
Securities Act.

 

2.           Exercise
of Warrant.

 

2.1.         Exercise
in Full. Subject to the provisions hereof, this Warrant may be exercised in full by the Holder hereof by surrender of this
Warrant, with the form of subscription at the end hereof duly executed by such Holder, to the Company at its principal office accompanied
by payment, in cash or by certified or official bank check payable to the order of the Company, in the amount obtained by multiplying
the number of shares of Purchase Stock issuable upon exercise of this Warrant by the Purchase Price per share, after giving effect
to all adjustments through the date of exercise.

 

2.2.         Partial
Exercise. Subject to the provisions hereof, this Warrant may be exercised in part by surrender of this Warrant in the manner
and at the place provided in Section 3.1 except that the amount payable by the Holder upon any partial exercise shall be the amount
obtained by multiplying (a) the number of shares of Warrant Shares (without giving effect to any adjustment therein) designated
by the Holder in the subscription at the end hereof, by (b) the Purchase Price per share. Upon any such partial exercise, the Company
at its expense will forthwith issue and deliver to or upon the order of the Holder hereof a new Warrant of like tenor, for the
remaining number of shares of Warrant Shares which may be purchased hereunder.

 

2.3          Cashless Exercise. In addition
to the method of payment set forth in Sections 2.1 and 2.2 and in lieu of any cash payment required thereunder, the Holder of the
Warrant shall have the right at any time and from time to time to exercise the Warrant in full or in part by surrendering this
Warrant in the manner and at the place specified in Section 3.1, specifying the number of shares for which this Warrant is being
exercised. The Company shall issue Holder the number of shares computed using the following formula:

 

    	2

    	 

    

 

	

        X=
	

	 	 	 
	where:	 	X = the number of Underlying Securities to be issued to Holder.
	 	 
	 	 	Y = the number of Underlying Securities for which this Warrant is being exercised.
	 	 
	 	 	A = the Purchase Price.
	 	 
	 	 	B = the Per Share Market Value of one share of Underlying Securities on the business day immediately preceding the date of such election

 

 

“Per
Share Market Value” means on any particular date (a) the closing sales price
per share of the Underlying Securities on such date on any registered national stock exchange
on which the Underlying Securities is then listed, or if there is no such closing sales price
on such date, then the closing sales price on such exchange or quotation system on the date nearest preceding such date, or (b)
if the Underlying Securities is not then listed on a registered national stock exchange, the
closing sales price for a share of Underlying Securities in
the over-the-counter market, as reported by the OTC Bulletin Board or the OTC Markets Group, Inc. (or similar organization or agency
succeeding to its functions of reporting prices) at the close of business on such date, or (c) if the Underlying Securities
is not then reported by the OTC Bulletin Board or the OTC Markets Group, Inc. (or similar organization
or agency succeeding to its functions of reporting prices), the fair market value of a share of Underlying Securities as
determined by the Board, acting in good faith. In determining the fair market value of any shares of Underlying Securities
no consideration shall be given to any restrictions on transfer of the Underlying Securities
imposed by agreement or by federal or state securities laws, or to the existence or absence of, or any limitations on, voting rights.

 

2.4.         Certain
Exercises. If this Warrant is to be exercised in connection with a registered public offering or sale of the Company,
such exercise may, at the election of the Holder, be conditioned on the consummation of the public offering or sale of the
Company, in which case such exercise shall not be deemed effective until the consummation of such transaction.

 

3.           Delivery
of Stock Certificates, etc., on Exercise. As soon as practicable after the exercise of this Warrant in full or in part, the
Company at its own expense (including the payment by it of any applicable issue taxes) will cause to be issued in the name of and
delivered to the Holder hereof, or as such Holder (upon payment by such Holder of any applicable transfer taxes) may direct, a
certificate or certificates for the number of fully paid and non-assessable shares of Warrant Shares or Other Securities to which
such Holder shall be entitled upon such exercise, plus, in lieu of any fractional share to which such Holder would otherwise be
entitled, cash equal to such fraction multiplied by the then-current Market Price of one full share, together with any other stock
or other securities and property (including cash, where applicable) to which such Holder is entitled upon such exercise pursuant
to Section 4 or otherwise.

 

    	3

    	 

    

 

4.           Adjustment
for Dividends in Other Stock, Property, etc.; Reclassification, etc. In case at any time or from time to time after the Original
Issue Date, the holders of Warrant Shares (or, if applicable, Other Securities) shall have received, or (on or after the record
date fixed for the determination of stockholders eligible to receive) shall have become entitled to receive, without payment therefor

 

(a)          other
or additional stock or other securities or property (other than cash) by way of dividend, or

 

(b)          any
cash paid or payable (including, without limitation, by way of dividend), or

 

(c)          other
or additional stock or other securities or property (including cash) by way of spin-off, split-up, reclassification, recapitalization,
combination of shares or similar corporate rearrangement,

 

then, and in each such case the Holder of this Warrant, upon
the exercise hereof as provided in Section 2, shall be entitled to receive the amount of stock and other securities and property
(including cash in the cases referred to in subdivisions (b) and (c) of this Section 4) which such Holder would hold on the date
of such exercise if on the Original Issue Date such Holder had been the Holder of record of the number of shares of Warrant Shares
called for on the face of this Warrant and had thereafter, during the period from the Original Issue Date to and including the
date of such exercise, retained such shares and all such other or additional stock and other securities and property (including
cash in the cases referred to in subdivisions (b) and (c) of this Section 4) receivable by such Holder as aforesaid during such
period, giving effect to all adjustments called for during such period by Section 5 hereof. If the number of shares of Warrant
Shares outstanding at any time after the date hereof is decreased by a combination or reverse stock split of the outstanding shares
of Common Stock, the Purchase Price per share shall be increased, and the number of shares of Warrant Shares purchasable under
this Warrant shall be decreased in proportion to such decrease in outstanding shares of Warrant Shares.

 

5.           Reorganization,
Consolidation, Merger, etc. In case the Company after the Original Issue Date shall (a) effect a reorganization, (b) consolidate
with or merge into any other entity or (c) transfer all or substantially all of its properties or assets to any other entity under
any plan or arrangement contemplating the dissolution of the Company, then, in each such case, the Holder of this Warrant, upon
the exercise hereof as provided in Section 3 at any time after the consummation of such reorganization, consolidation or merger
or the effective date of such dissolution, as the case may be, shall be entitled to receive (and the Company shall be entitled
to deliver), in lieu of the Underlying Securities issuable upon such exercise prior to such consummation or such effective date,
the stock and other securities and property (including cash) to which such Holder would have been entitled upon such consummation
or in connection with such dissolution, as the case may be, if such Holder had so exercised this Warrant immediately prior thereto,
all subject to further adjustment thereafter as provided in this Section 5; provided that if the sole consideration to which such
Holder would have been entitled upon such consummation or in connection with such dissolution, as the case may be, if such Holder
had so exercised this Warrant immediately prior thereto, is cash, the Warrant shall be terminated upon such consummation or dissolution.
The Company shall not effect any such reorganization, consolidation, merger or sale, unless prior to or simultaneously with the
consummation thereof, the successor corporation resulting from such consolidation or merger or the corporation purchasing such
assets or the appropriate corporation or entity shall assume, by written instrument, the obligation to deliver to each Holder the
shares of stock, cash, other securities or assets to which, in accordance with the foregoing provisions, each Holder may be entitled
to and all other obligations of the Company under this Warrant. In any such case, if necessary, the provisions set forth in this
Section 5 with respect to the rights thereafter of the Holders shall be appropriately adjusted so as to be applicable, as nearly
as may reasonably be, to any Other Securities or assets thereafter deliverable on the exercise of the Warrants.

 

    	4

    	 

    

 

6.           Further
Assurances. The Company will take all such action as may be necessary or appropriate in order that the Company may validly
and legally issue fully paid and non-assessable shares of stock upon the exercise of all Warrants from time to time outstanding.

 

7.           Officer's
Certificate as to Adjustments. In each case of any adjustment or readjustment in the shares of Warrant Shares (or Other Securities)
issuable upon the exercise of the Warrants, the Company will issue a certificate setting forth such adjustment or readjustment
and the basis therefor.

 

8.           Notices
of Record Date, etc. In the event of

 

(a)          any
taking by the Company of a record of its stockholders for the purpose of determining the stockholders thereof who are entitled
to receive any dividend or other distribution, or any right to subscribe for, purchase or otherwise acquire any shares of stock
of any class or any other securities or property, or to receive any other right, or for the purpose of determining stockholders
who are entitled to vote in connection with any proposed capital reorganization of the Company, any reclassification or recapitalization
of the capital stock of the Company or any transfer of all or substantially all the assets of the Company to or consolidation or
merger of the Company with or into any other person, or

 

(b)          any
voluntary or involuntary dissolution, liquidation or winding-up of the Company, or

 

(c)          any
proposed issue or grant by the Company of any Common Stock, or any other securities, or any right or option to subscribe for, purchase
or otherwise acquire any shares of stock of any class or any other securities (other than the issue of Common Stock on the exercise
of the Warrants),

 

    	5

    	 

    

 

then and in each such event the Company will mail or cause to
be mailed to each Holder of a Warrant a notice specifying (i) the date on which any such record is to be taken for the purpose
of such dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, (ii) the
date on which any such reorganization, reclassification, recapitalization, transfer, consolidation, merger, dissolution, liquidation
or winding-up is to take place, and the time, if any, as of which the Holders of record of Underlying Securities shall be entitled
to exchange their shares of Underlying Securities for securities or other property deliverable upon such reorganization, reclassification,
recapitalization, transfer, consolidation, merger, dissolution, liquidation or winding-up and (iii) the amount and character of
any stock or other securities, or rights or options with respect thereto, proposed to be issued or granted, the date of such proposed
issue or grant and the persons or class of persons to whom such proposed issue or grant and the persons or class of persons to
whom such proposed issue or grant is to be offered or made. Such notice shall be given at least 10 days prior to the date therein
specified.

 

9.           Reservation
of Stock, etc., Issuable on Exercise of Warrants. The Company will at all times reserve and keep available, solely for issuance
and delivery upon the exercise of the Warrants, all shares of Warrant Shares (or Other Securities) from time to time issuable upon
the exercise of the Warrants.

 

10.         Notices,
etc. All notices and other communications from the Company to the Holder of this Warrant shall be delivered by fax or courier,
at such address as may have been furnished to the Company in writing by such Holder, or, until an address is so furnished, to and
at the address of the last Holder of this Warrant who has so furnished an address to the Company.

 

11.         Miscellaneous.
This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the
Company and the Holder or as otherwise provided in the Subscription Agreement. This Warrant shall be governed by and construed
and enforced in accordance with the General Corporation Law of the State of Delaware without regard to principles of conflicts
of law. Each party hereby irrevocably consents and submits to the jurisdiction of any New York State or United States Federal Court
sitting in the State of New York, County of New York, over any action or proceeding arising out of or relating to this Agreement
and irrevocably consents to the service of any and all process in any such action or proceeding by registered mail addressed to
such party at its address specified herein (or as otherwise noticed to the other party). Each party further waives any objection
to venue in New York and any objection to an action or proceeding in such state and county on the basis of forum non conveniens.
Each party also waives any right to trial by jury.

 

	Dated: __________ __, 2011	 	NANO VIBRONIX, INC.
	 	 	 	By:	 
	 	 	 	Name:
	Attest:	 	 	Title:

 

    	6

    	 

    

 

FORM OF SUBSCRIPTION

 

(To be signed only upon exercise of Warrant)

 

To: NANO VIBRONIX, INC.

 

The undersigned, the Holder of the within
Warrant, hereby irrevocably elects to exercise the purchase right represented by such Warrant for, and to purchase thereunder,
_________ shares of Warrant Shares of Nano Vibronix, Inc., and herewith makes payment therefor

 

(i) of $_____________ or

 

(ii) by surrender of the number of Warrants included
in the within Warrant required for full exercise pursuant to Section 2.3 of the Warrant,

and requests that the certificates for such shares be issued
in the name of, and delivered to, ___________________, whose address is _______________________.

 

	Dated:	 
	 	 
	 	 
	 	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)
	 	 
	 	 
	 	(Address)

 

    	7Exhibit 10.9

 

 

FIFTH AMENDED AND RESTATED

SECURITIES PURCHASE AGREEMENT

 

THIS FIFTH AMENDED
AND RESTATED SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into as of December 9, 2013,
by and among Nano Vibronix, Inc., a Delaware corporation (the “Company”), and Globis Overseas Fund, Ltd.
(the “Investor”).

 

WHEREAS, the Company
and the Investor entered into that certain Securities Purchase Agreement dated as of February 5, 2013 (the “Original
SPA”) and, in connection therewith, the Company issued to the Investor that certain (i) Secured Convertible Promissory
Note dated February 5, 2013 in the principal amount of $20,000 and (ii) a warrant to purchase 52,632 shares of common stock of
the Company, dated February 5, 2013 (the “February Warrant”);

 

WHEREAS, the Company
and the Investor entered into that certain Amended and Restated Securities Purchase Agreement dated as of March 28, 2013 (the “March
SPA”) to amend and restate the Original SPA and, in connection therewith, the Company issued to the Investor that
certain (i) Amended and Restated Secured Convertible Promissory Note dated March 28, 2013 in the principal amount of $40,000 (the
“March Note”) and (ii) a warrant to purchase 52,632 shares of common stock of the Company, dated March
28, 2013 (the “March Warrant”); and

 

WHEREAS, the Company
and the Investor entered into that certain Second Amended and Restated Securities Purchase Agreement dated as of June 3, 2013 (the
“June SPA”) to amend and restate the March SPA and, in connection therewith, the Company issued to the
Investor that certain (i) Second Amended and Restated Secured Convertible Promissory Note dated June 3, 2013 in the principal amount
of $60,000 (the “June Note”) and (ii) a warrant to purchase 52,632 shares of common stock of the Company,
dated June 3, 2013 (the “June Warrant”); and

 

WHEREAS, the Company
and the Investor entered into that certain Third Amended and Restated Securities Purchase Agreement dated as of August 5, 2013
(the “August SPA”) to amend and restate the June SPA and, in connection therewith, the Company issued
to the Investor that certain (i) Third Amended and Restated Secured Convertible Promissory Note dated August 5, 2013 in the principal
amount of $80,000 (the “August Note”) and (ii) a warrant to purchase 52,632 shares of common stock of
the Company, dated August 5, 2013 (the “August Warrant”); and

 

WHEREAS, the Company
and the Investor entered into that certain Fourth Amended and Restated Securities Purchase Agreement dated as of October 7, 2013
(the “Existing SPA”) to amend and restate the August SPA and, in connection therewith, the Company issued
to the Investor that certain (i) Fourth Amended and Restated Secured Convertible Promissory Note dated October 7, 2013 in the principal
amount of $100,000 (the “Existing Note”) and (ii) a warrant to purchase 52,632 shares of common stock
of the Company, dated October 7, 2013 (the “October Warrant”; and, together with the February Warrant,
the March Warrant, the June Warrant and the August Warrant, the “Existing Warrants”); and

 

WHEREAS, the Company
and the Investor desire to amend and restate the Existing SPA and the Existing Note to increase the principal amount outstanding
thereunder and to issue an additional warrant as set forth herein.

 

NOW THEREFORE, for
good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties agree that the Existing
SPA is hereby amended and restated in its entirety as follows:

 

    	 

    	 

    

  

SECTION
1

 

DEFINITIONS

 

1.1           Definitions.
Capitalized but otherwise undefined terms used herein shall have the meanings provided therefor in the Convertible Note. In addition
to the terms defined elsewhere in this Agreement and the Convertible Note, the following terms have the meanings indicated:

 

“Business
Day” means any day which is not a Saturday or Sunday or a legal holiday on which banks are authorized or required
to be closed in New York, New York.

 

“Collateral”
has the meaning ascribed to such term in the Convertible Note.

 

“Common
Stock” means the common stock of the Company.

 

“Convertible
Note” shall have the meaning ascribed to such term in Section 2.1.

 

“Governmental
Authority” shall mean any federal, state, local or other governmental department, commission, board, bureau, agency
or other instrumentality or authority, domestic or foreign, exercising executive, legislative, judicial, regulatory or administrative
authority or functions of or pertaining to government.

 

“Lien”
has the meaning ascribed to such term in the Convertible Note.

 

“Material
Adverse Effect” shall mean (i) a material and adverse effect on the legality, validity or enforceability of
any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, condition (financial
or otherwise) or prospects of the Company and its direct or indirect Subsidiaries, taken as a whole on a consolidated basis, or
(iii) a material and adverse impairment of the Company’s ability to perform fully on a timely basis its obligations
under any of the Transaction Documents to which such Person is party.

 

“Note Conversion
Shares” means the shares of Common Stock issuable upon the conversion of the Convertible Note in accordance with
Section 5 of the Convertible Note.

 

“Organic
Document” means, relative to any Person, its articles or certificate of incorporation, or certificate of limited
partnership or formation, its bylaws, partnership or operating agreement or other organizational documents, and all stockholders
agreements, voting trusts and similar arrangements applicable to any of its capital stock, partnership interests or other ownership
interests.

 

“Person”
means any individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, or joint stock company.

 

“SEC”
means the Securities and Exchange Commission, or any Governmental Authority succeeding to any of its principal functions.

 

“Securities”
means the Convertible Note, the Warrants, the Note Conversion Shares and the Warrant Shares.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

    	2

    	 

    

  

“Subsidiary”
shall mean, with respect to any Person (herein referred to as the “parent”), any corporation, limited liability company,
partnership, association or other business entity (a) of which securities of other ownership interests representing more than 50%
of the equity or more than 50% of the ordinary voting power or more than 50% of the general partnership interests are, at the time
any determination is being made, owned, controlled or held by the parent, or (b) that is, at any time any determination is made,
otherwise controlled by, the parent or one or more Subsidiaries of the parent and one or more Subsidiaries of the parent.

 

“Transaction
Documents” means this Agreement, the Convertible Note, the Warrants and any other and all other certificates, documents,
agreements and instruments delivered to the Investor under or in connection with this Agreement, the Convertible Note or the Warrants.

 

“Warrant
Shares” means the shares of Common Stock into which the Warrants are exercisable, pursuant to terms of the applicable
Warrant.

 

“Warrants”
means, collectively, the Existing Warrants and the Additional Warrant.

 

SECTION
2

 

ISSUANCE
OF SECURITIES

 

2.1           Issuance
of Securities. Subject to the terms and conditions of this Agreement, the Company shall issue and sell to the Investor the
fifth amended and restated secured convertible promissory note, the form of which is attached hereto as Exhibit A (the “Convertible
Note”), in the principal amount of $120,000 (the “Principal Amount”), the Existing Warrants
(which were previously delivered by the Company on February 5, 2013, March 28, 2013, June 3, 2013, August 5, 2013 and October 7,
2013, respectively) and a warrant to purchase an aggregate of up to 52,632 shares of Common Stock, the form of which is attached
hereto as Exhibit B (the “Additional Warrant”), against payment by the Investor to (or to the
order of) the Company of $120,000 (the “Purchase Price”) (of which $20,000 was paid by the Investor on
February 5, 2013, $20,000 was paid by the Investor on March 28, 2013, $20,000 was paid by the Investor on June 3, 2013, $20,000
was paid by the Investor on August 5, 2013 and $20,000 was paid by the Investor on October 7, 2013). 

 

2.2           Delivery.
On the date hereof, (a) the Company shall execute and deliver to the Investor the Convertible Note and the Additional Warrant,
and (b) the Investor shall deliver to the Company a check or wire transfer of immediately available funds in an amount equal
to $20,000. Each of the Convertible Note and the Additional Warrant shall be a binding obligation of the Company upon execution
thereof by the Company and delivery thereof to the Investor. The Company acknowledges that it already received $100,000 of the
Purchase Price ($20,000 paid by the Investor on February 5, 2013, $20,000 paid by the Investor on March 28, 2013, $20,000 paid
by the Investor on June 3, 2013, $20,000 paid by the Investor on August 5, 2013 and $20,000 paid by the Investor on October 7,
2013) in connection with the Original SPA, the March SPA, the June SPA, the August SPA and the Existing SPA, such that only $20,000
of the Purchase Price is due on the date hereof, and the Investor acknowledges that it received the February Warrant on February
5, 2013 in connection with the Original SPA, the March Warrant on March 28, 2013 in connection with the March SPA, the June Warrant
on June 3, 2013 in connection with the June SPA, the August Warrant on August 5, 2013 in connection with the August SPA and the
October Warrant on October 7, 2013 in connection with the Existing SPA.

 

    	3

    	 

    

  

SECTION
3

 

REPRESENTATIONS
AND WARRANTIES OF the investor

 

The Investor hereby
represents, warrants and covenants to the Company as follows:

 

3.1           Purchase
for Own Account. The Investor represents that it is acquiring the Securities solely as an investment for such Person’s
own account not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Investor
has no present intention of selling, granting any participation in, or otherwise distributing the same. The acquisition by the
Investor of any of the Securities shall constitute confirmation of the representation by the Investor that the Investor does not
have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person
or to any third person, with respect to any of the Securities.

 

3.2           Investment
Experience. Either (a) the Investor or its officers, directors, managers or controlling persons has a preexisting personal
or business relationship with the Company or its officers, directors or controlling persons, or (b) the Investor, by reason of
its own business and financial experience, has the capacity to protect its own interests in connection with the investment contemplated
hereby. The Investor represents that it is an investor in securities of companies in the development stage and acknowledges that
it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial
or business matters that it is capable of evaluating the merits and risks of the investment in the Securities. The Investor acknowledges
that any investment in the Securities involves a high degree of risk, and represents that it is able, without materially impairing
its financial condition, to hold the Securities for an indefinite period of time and to suffer a complete loss of its investment.

 

3.3           Accredited
Investor. The Investor represents that it is an “accredited investor” within the meaning of SEC Rule 501 of Regulation
D, as presently in effect.

 

3.4           Restrictions
on Transfer. The Investor understands that the Securities are characterized as “restricted securities” under the
federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and
that under such laws and applicable regulations such securities may be resold without registration under the Securities Act, only
in certain limited circumstances. In this connection, the Investor represents that it is familiar with SEC Rule 144, as presently
in effect, and understands the resale limitations imposed thereby and by the Securities Act.

 

3.5           Authorization
and Power. The Investor has the requisite power and authority to enter into and perform this Agreement and the other Transaction
Documents that it is a party to and to purchase the Convertible Note and the Warrants being sold to it hereunder. The execution,
delivery and performance of this Agreement and the other Transaction Documents that the Investor is a party to by the Investor
and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action,
and no further consent or authorization of the Investor or its Board of Directors, members or managers, as the case may be, is
required. Each of this Agreement and the Transaction Documents that the Investor is a party to has been duly authorized, executed
and delivered by the Investor and constitutes, or shall constitute when executed and delivered, a valid and binding obligation
of the Investor enforceable against the Investor in accordance with the terms thereof.

 

    	4

    	 

    

  

SECTION
4

 

Representations
and Warranties of the Company

 

The Company hereby
represents and warrants to the Investor that:

 

4.1           Organization,
Good Standing and Qualification; Licenses. Each of the Company and its Subsidiaries is duly organized, validly existing and
in good standing under the laws of the jurisdiction of its incorporation or organization and has all requisite power and authority,
and holds all governmental licenses, permits, registrations and other approvals required under applicable law, to own and hold
under lease its property and to carry on its business as now conducted and as proposed to be conducted, except where the failure
to hold any such licenses, permits, registrations and other approvals could not result in a Material Adverse Effect. Each of the
Company and each of its Subsidiaries is qualified to do business in each jurisdiction where the nature of its properties of the
conduct of its business requires it to be so qualified to do business and where the failure so to qualify could result in a Material
Adverse Effect.

 

4.2           Authorization.
All action on the part of the Company necessary for the authorization, execution and delivery of this Agreement, the performance
of all obligations of the Company hereunder, and the authorization, issuance (or reservation for issuance), sale and delivery of
the Securities, has been taken or will be taken prior to the date hereof. Each of the Transaction Documents constitutes the valid
and legally binding obligation of the Company, enforceable against the Company in accordance with its terms.

 

4.3           Absence
of Required Consents; No Violations. No consent, approval, order or authorization of, or registration, qualification, designation,
declaration or filing with, any Governmental Authority on the part of the Company or any of its Subsidiaries is required in connection
with the consummation of the transactions contemplated by the Transaction Documents, except for the filing with the SEC of a Form
D, and such filing(s) pursuant to applicable state securities laws as may be necessary, which filings will be timely effected after
the delivery of the Securities pursuant to Section 2.2, and recordings or filings in connection with the perfection of the
Liens on the Collateral in favor of the Investor. Neither the Company nor any of its Subsidiaries is in violation or default (a)
of any provision of its Organic Documents, (b) of any instrument, judgment, order, writ, decree or contract to which it is a party
or by which it is bound, or (c) of any provision of any federal or state statute, rule or regulation applicable to the Company,
except in the cases of clause (b) and (c) above, for such violations or defaults that would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. The execution, delivery and performance of the Transaction Documents
and the consummation of the transactions contemplated thereby will not result in any such violation or be in conflict with or constitute,
with or without the passage of time and giving of notice, either a default under any such provision, instrument, judgment, order,
writ, decree or contract or an event that results in the creation of any Lien upon any material assets of the Company, any of its
Subsidiaries or the suspension, revocation, impairment, forfeiture or nonrenewal of any permit, license, authorization or approval
applicable to the Company or any of its Subsidiaries, their business or operations or any of their assets or properties and which
would result in a Material Adverse Effect.

 

4.4           Convertible
Note and Warrant. All representations and warranties of the Company contained in the Convertible Note and the Warrants are
true and correct as of the date hereof.

 

4.5           Licenses
and Intellectual Property Rights. The Company and each of its Subsidiaries possess all licenses, patents, trademarks, trade
names, service marks, copyrights, and other intellectual property rights, free from burdensome restrictions, necessary to enable
them to conduct their respective business, the absence of which could result in a Material Adverse Effect.

 

    	5

    	 

    

 

4.6           Disclosure.
None of the representations or warranties made by the Company herein as of the date of such representations and warranties, and
none of the statements contained in any other information with respect to the Company and its properties and assets, including
each exhibit or report, furnished by or on behalf of the Company to the Investor in connection herewith, contains any untrue statement
of a material fact or omits any material fact required to be stated therein or necessary to make the statements made therein,
in the light of the circumstances under which they are made, not misleading.

 

4.7           Offering.
Subject in part to the truth and accuracy of the Investor’s representations set forth in Section 3 of this Agreement,
the offer, sale and issuance of the Securities as contemplated by this Agreement is exempt from the registration requirements of
the Securities Act and will not result in a violation of the qualification or registration requirements of the any applicable state
securities laws, and neither the Company nor any authorized agent acting on its behalf will take any action hereafter that would
cause the loss of such exemption.

 

4.8           Valid
Issuance of Note Conversion Shares and Warrant Shares. The Note Conversion Shares, when issued, sold and delivered in accordance
with the terms of the Convertible Note for the consideration specified therein and the Warrant Shares, when issued, sold and delivered
in accordance with the terms of the Warrants for the consideration specified therein, will be duly and validly issued, fully paid,
and nonassessable, and will be free of restrictions on transfer other than restrictions on transfer under this Agreement and under
applicable state and federal securities laws.

 

4.9           Collateral.

 

(a)          The
Company’s chief executive office and principal place of business (as of the date of this Agreement) is located at the address
set forth in Schedule 1; the Company’s jurisdiction of organization and organizational identification number are set
forth in Schedule 1; the Company’s exact legal name is as set forth in the first paragraph of this Agreement;
and all other locations where the Company conducts business or Collateral is kept (as of the date of this Agreement) are set forth
in Schedule 2.

 

(b)          The
Company has rights in or the power to transfer the Collateral, and the Company is the legal and beneficial owner of the Collateral,
free from any Lien, and has good and marketable title thereto.

 

(c)          All
of the Company’s U.S. and foreign patents and patent applications, copyrights (whether or not registered), applications for
copyright, trademarks, service marks and trade names (whether registered or unregistered), and applications for registration of
such trademarks, service marks and trade names, are set forth in Schedule 2.

 

SECTION
5

 

MISCELLANEOUS

 

5.1           Survival
of Representations, Warranties and Covenants. The warranties, representations and covenants of the Company, the Investor contained
in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and shall in no way be affected
by any investigation of the subject matter thereof made by or on behalf of the Investor or the Company.

 

    	6

    	 

    

  

5.2           Successors
and Assigns. Except as otherwise provided therein, the terms and conditions of this Agreement and the other Transaction Documents
shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of
any Securities); provided, however, that the Company may not assign or transfer its rights or obligations hereunder
or under the other Transaction Documents without the prior written consent of the Investor. The Securities shall be freely transferable,
without restriction, subject to compliance with applicable securities laws. Nothing in this Agreement, express or implied, is intended
to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations,
or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

 

5.3           Governing
Law; Venue; Jury Trial Waiver. 

 

(a)          This
Agreement is to be construed in accordance with and governed by the laws of the State of New York.

 

(b)          Each
party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York,
Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an
inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such
party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED
HEREBY.

 

5.4           Counterparts.
This Agreement may be executed in several counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. The delivery of an executed counterpart of a signature page of this Agreement by telecopy
or other electronic imaging means shall be effective as delivery of a manually executed counterpart of this Agreement.

 

5.5           Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement. 

 

5.6           Notices.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt or: (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic
mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s
next Business Day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage
prepaid, or (d) one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying
next Business Day delivery, with written verification of receipt. All communications for the Company shall be sent to 105 Maxess
Road, Suite S124, Melville, NY 11747 and all communications for the Investor shall be sent to 805 Third Avenue, 15th Floor, New
York, NY 10022, or to such e-mail address, facsimile number or address as subsequently modified by written notice given in accordance
with this Section 5.6.

 

    	7

    	 

    

  

5.7           Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or prospectively), only if such amendment, modification or waiver
is in writing and only with the written consent of the Company and the Investor. Any amendment or waiver effected in accordance
with this section shall be binding upon each holder of any Securities acquired under this Agreement at the time outstanding (including
securities into which such Securities are convertible), each future holder of all such Securities, and the Company.

 

5.8           Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded
from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable
in accordance with its terms.

 

5.9           Expenses.
The Company shall pay the fees and expenses of the advisors, counsel, accountants and other experts of the Company and the Investor,
if any, and all other expenses, incurred by the Company and the Investor incident to the negotiation, preparation, execution, delivery
and performance of the Transaction Documents.

 

5.10         Register.
The Company shall maintain at its principal executive offices a register for the Securities, in which the Company shall record
the name and address of the person in whose name the Securities have been issued (including the name and address of each transferee)
and the amount of the Securities held by such person. The Company shall keep the register open and available during business hours
for inspection by the Investors or their legal representatives upon prior written notice.

 

5.11         Interpretation.
In this Agreement and the other Transaction Documents, except to the extent the context otherwise requires: (a) any reference
in this Agreement or other Transaction Document to a Section, a Schedule or an Exhibit is a reference to a Section thereof,
a schedule thereto or an exhibit thereto, respectively, and to a subsection thereof or a clause thereof is, unless otherwise
stated, a reference to a subsection or a clause of the Section or subsection in which the reference appears; (b) the
words “hereof,” “herein,” “hereto,” “hereunder” and the like mean and refer to
this Agreement or other Transaction Document as a whole and not merely to the specific Section, subsection, paragraph or clause
in which the respective word appears; (c) the meaning of defined terms shall be equally applicable to both the singular and
plural forms of the terms defined; (d) references to agreements and other contractual instruments shall be deemed to include
all subsequent amendments and other modifications thereto; (e) references to statutes or regulations are to be construed as
including all statutory and regulatory provisions consolidating, amending or replacing the statute or regulation referred to; and
(f) the captions and headings are for convenience of reference only and shall not affect the construction of this Agreement
or other Transaction Document.

 

5.12         Further
Assurances. Each party agrees to cooperate fully with the other parties and to execute such further instruments, documents
and agreements and to give such further written assurance as may be reasonably requested by any other party to evidence and reflect
the transactions described in this Agreement and the other Transaction Documents and contemplated hereby and thereby and to carry
into effect the intents and purposes of this Agreement and the other Transaction Documents.

 

5.13         Reservation
of Stock. The Company covenants that it will (a) reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of Common Stock upon the conversion of the Convertible Note and the exercise of the Warrants
and/or (b) take all necessary steps, within the opinion of legal counsel, to amend the Company’s certificate of incorporation
to provide sufficient reserves of shares of Common Stock issuable upon conversion of the Convertible Note and the exercise of the
Warrants.

 

    	8

    	 

    

  

5.14         Notices
for Collateral. 

 

(a)          The
Company shall give prompt written notice to the Investor (and in any event not later than 30 days following any change described
below in this subsection) of:  (i) any change in the location of the Company’s chief executive office or principal
place of business; (ii) any change in the locations set forth in Schedule 1; (iii) any change in the Company’s
name; (iv) any changes in the Company’s identity or
structure in any manner which might make any financing statement filed hereunder incorrect or misleading; (v) any change in
the Company’s registration as an organization (or any new such registration); or (vi) any change in the Company’s
jurisdiction of organization; provided that the Company shall not locate any Collateral outside of the United States nor
shall the Company change its jurisdiction of organization to a jurisdiction outside of the United States.

 

(b)          If
and when the Company shall obtain rights to any new patents, trademarks, service marks, trade names or copyrights, or otherwise
acquire or become entitled to the benefit of, or apply for registration of, any of the foregoing, the Company (i) shall promptly
notify the Investor thereof, and (ii) hereby authorizes the Investor to modify, amend, or supplement Schedule 2
and from time to time to include any of the foregoing and make all necessary or appropriate filings with respect thereto.

 

5.15         Power
of Attorney. (a)          The Investor shall have the right to, in the name
of the Company, or in the name of the Investor or otherwise, upon notice to but without the requirement of assent by the Company,
and the Company hereby constitutes and appoints the Investor (and any of the Investor’s officers, employees or agents designated
by the Investor) as the Company’s true and lawful attorney-in-fact, with full power and authority to: (i) sign and file any
of the financing statements and other documents and instruments which must be executed or filed to perfect or continue perfected,
maintain the priority of or provide notice of the Investor’s security interest in the Collateral; (ii) assert, adjust, sue
for, compromise or release any claims under any policies of insurance; (iii) give notices of control, default or exclusivity (or
similar notices) under any account control agreement or similar agreement with respect to exercising control over deposit accounts
or securities accounts; and (iv) execute any and all such other documents and instruments, and do any and all acts and things for
and on behalf of the Company, which the Investor may deem reasonably necessary or advisable to maintain, protect, realize upon
and preserve the Collateral and the Investor’s security interest therein and to accomplish the purposes of this Agreement.
The Investor agrees that, except upon and during the continuance of an event of default under the Convertible Note, it shall not
exercise the power of attorney, or any rights granted to the Investor, pursuant to clauses (ii), (iii) and (iv). The foregoing
power of attorney is coupled with an interest and irrevocable so long as the obligations under the Convertible Note have not been
paid and performed in full. The Company hereby ratifies, to the extent permitted by law, all that the Investor shall lawfully and
in good faith do or cause to be done by virtue of and in compliance with this Section 5.15.

 

5.16         Amendment
and Restatement. The Company and the Investor agree that: (a) the Obligations (as defined in the Convertible Note) represent,
among other things, the restatement, renewal, amendment and modification of the “Obligations” (as defined in the Existing
Note); (b) this Agreement is intended to, and does hereby, restate, renew, amend, modify, supersede and replace the Existing SPA
in its entirety; and (c) the entering into and performance by the Company and the Investor of their respective obligations under
the Transaction Documents and the transactions evidenced hereby and thereby do not constitute a novation nor shall they be deemed
to have terminated, extinguished or discharged the indebtedness under the Existing Note, all of which indebtedness shall continue
under and be governed by this Agreement and the Convertible Note. All references in the other Transaction Documents to the Existing
SPA shall henceforth include references to this Agreement, as may, from time to time, be further amended, modified, extended, and/or
renewed. To the extent permitted by applicable Law, any and all of the terms and provisions of the other Transaction Documents
are hereby amended and modified wherever necessary, even though not specifically addressed herein, so as to conform to the amendments
and modifications set forth herein.

 

    	9

    	 

    

  

5.17         Ratifications.
The Company hereby (a) ratifies and confirms all provisions of the Existing SPA and the Convertible Note and all other Transaction
Documents, and (b) ratifies and confirms that all guaranties, assurances, and liens granted, conveyed, or assigned to the Investor
under the Existing Note are not released, reduced, or otherwise adversely affected by this Agreement and continue to guarantee,
assure, and secure full payment and performance of the present and future obligations of the Company under this Agreement, the
Convertible Note and the Transaction Documents.

 

5.18         Entire
Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties with respect
to the subject matter hereof and no party shall be liable or bound to any other party in any manner by any warranties, representations
or covenants except as specifically set forth herein or therein. 

 

(Remainder of page
intentionally left blank; signature pages follow)

 

    	10

    	 

    

 

IN WITNESS WHEREOF, the parties have executed
this Fifth Amended and Restated Securities Purchase Agreement as of the date first above written.

 

	 	NANO VIBRONIX, INC., 
	 	as the Company
	 	 	 
	 	By: 	/s/ Harold Jacob
	 	 	 
	 	Name: 	Harold Jacob
	 	 	 
	 	Title: 	Chief Executive Officer
	 	 	 
	 	GLOBIS OVERSEAS FUND LTD., 
	 	as the Investor
	 	 	 
	 	By: 	/s/ Paul Packer
	 	 	 
	 	Name: 	Paul Packer
	 	 	 
	 	Title: 	Managing Member of the General Partner of the 
	 	 	Investment Manager

  

    	 

    	 

    

 

EXHIBIT A

 

FORM OF SECURED CONVERTIBLE
NOTE

 

    	 

    	 

    

 

EXHIBIT B

 

FORM OF WARRANT TO
PURCHASE COMMON STOCK

 

    	 

    	 

    

 

SCHEDULE 1

 

COMPANY INFORMATION

 

    	 

    	 

    

 

SCHEDULE 2

 

COMPANY INTELLECTUAL
PROPERTY

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}]]